Trial Profile
An ascending single dose study of the safety and pharmacokinetics of IMA-638 administered to healthy Japanese subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Dec 2015
Price :
$35
*
At a glance
- Drugs Anrukinzumab (Primary)
- Indications Asthma; Ulcerative colitis
- Focus Adverse reactions
- 24 Jul 2007 Status changed from recruiting to completed.
- 08 Oct 2006 New trial record.